ClinicalTrials.gg
CompletedNCT02016716Updated Nov 8, 2018Results posted

A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis

A Phase 3 interventional study of Romosozumab 90 mg/mL and Placebo 90 mg/mL in Postmenopausal Osteoporosis, sponsored by Amgen. Completed at 12 sites in 3 countries. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-11-08.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
294
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.

Enrollment
5th of 12
294 · median 268
Started
2013
with 1 other
Phase 3
6 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
9 of 12
Amgen

Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one is the 5th largest by enrollment, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 6th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing romosozumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

The purpose of this study is to compare 2 formulations of romosozumab (AMG 785) on bone mineral density (BMD) in postmenopausal women with osteoporosis.

Read the detailed description

Upon confirmation of eligibility, participants were randomized in a 22:5:22:5 ratio to the following treatment groups:

  • Romosozumab 90 mg/mL
  • Placebo 90 mg/mL
  • Romosozumab 70 mg/mL
  • Placebo 70 mg/mL

After completing a 6-month treatment period, participants entered a 3-month follow-up period with an end of study (EOS) at month 9.

For the analysis of efficacy endpoints, the 2 placebo groups were combined into a single placebo group. For safety analyses, the data for placebo were presented separately for each group.

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • Postmenopausal Osteoporosis
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

women with osteoporosis at high risk for fracture defined as

  • BMD T-score ≤ -2.50 at the lumbar spine, total hip, or femoral neck AND
  • a history of fragility fracture or at least 2 other risk factors

Exclusion criteria

Exclusion Criteria:

  • BMD T score \< -3.50 at the total hip or femoral neck.
  • History of hip fracture.
  • History of metabolic or bone disease (except osteoporosis).
  • Use of agents affecting bone metabolism.
  • Vitamin D insufficiency.
  • History of solid organ or bone marrow transplants.
  • Hyper- or hypocalcemia.
  • Hyper- or hypothyroidism.
  • Hyper- or hypoparathyroidism.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
294 participants (actual)

Study arms

  • Experimental
    Romosozumab 90 mg/mL

    Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous (SC) 1.17 mL injections of a 90 mg/mL solution, for 6 months.

    Drug: Romosozumab 90 mg/mL

  • Experimental
    Placebo 90 mg/mL

    Participants received matching placebo administered as 2 subcutaneous injections of 1.17 mL every month for 6 months.

    Drug: Placebo 90 mg/mL

  • Experimental
    Romosozumab 70 mg/mL

    Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1.0 mL injections of a 70 mg/mL solution, for 6 months.

    Drug: Romosozumab 70 mg/mL

  • Placebo comparator
    Placebo 70 mg/mL

    Participants received matching placebo administered as 3 subcutaneous injections of 1.0 mL every month for 6 months.

    Drug: Placebo 70 mg/mL

Interventions

  • DrugRomosozumab 90 mg/mL

    Drug page: Romosozumab

    Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).

    Also known as: AMG 785, EVENITY™

  • DrugPlacebo 90 mg/mL

    Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.

  • DrugRomosozumab 70 mg/mL

    Drug page: Romosozumab

    Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.

    Also known as: AMG 785, EVENITY™

  • DrugPlacebo 70 mg/mL

    Placebo administered as 3 SC injections with the 1.0 mL glass PFS.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine

    Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

    Time frame: Baseline and month 6

Secondary outcomes

  1. Percent Change From Baseline in Total Hip BMD

    Total hip BMD was measured using DXA. The analysis was based on an ANCOVA model adjusted for treatment and baseline total hip BMD T-score.

    Time frame: Baseline and month 6

  2. Percent Change From Baseline in Femoral Neck BMD

    Femoral neck BMD was measured using DXA. The analysis was based on an ANCOVA model adjusted for treatment and baseline femoral neck BMD T-score.

    Time frame: Baseline and month 6

  3. Percent Change From Baseline in N-Terminal Propeptide Type 1 Procollagen (P1NP)

    Time frame: Baseline, month 1, month 3, and month 6

  4. Percent Change From Baseline in Serum C-Telopeptide (CTX)

    Time frame: Baseline, month 1, month 3, and month 6

07

Results

Posted Nov 8, 2018

Participant flow

This study was conducted at 11 centers: 7 in Poland, 2 in the Czech Republic, and 2 in the United States. The first participant enrolled on 03 December 2013 and the last participant enrolled on 07 March 2014.

Participant flow — Overall Study
MilestonePlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mL
Started53118123
Received study treatment53118123
Completed47110117
Not completed686
Withdrew: Withdrawal by subject555
Withdrew: Protocol-specified criteria010
Withdrew: Lost to follow-up121

Outcome measures

PrimaryPercent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine

Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA).

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine
percent changePlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mL
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine0.8 (-0.4 to 2.1)9.6 (8.8 to 10.4)9.2 (8.4 to 10.0)
Statistical analysis
  • Romosozumab 70 mg/mL vs Romosozumab 90 mg/mL · Least squares mean difference: -0.4 · 95% CI -1.5 to 0.7Based on ANCOVA model adjusting for treatment, and baseline lumbar spine BMD T-score.
SecondaryPercent Change From Baseline in Total Hip BMD

Total hip BMD was measured using DXA. The analysis was based on an ANCOVA model adjusted for treatment and baseline total hip BMD T-score.

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Hip BMD
percent changePlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mL
Percent Change From Baseline in Total Hip BMD-0.0 (-0.9 to 0.8)3.9 (3.4 to 4.4)3.4 (2.9 to 4.0)
SecondaryPercent Change From Baseline in Femoral Neck BMD

Femoral neck BMD was measured using DXA. The analysis was based on an ANCOVA model adjusted for treatment and baseline femoral neck BMD T-score.

Time frame:
Baseline and month 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Femoral Neck BMD
percent changePlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mL
Percent Change From Baseline in Femoral Neck BMD-0.5 (-1.5 to 0.5)3.1 (2.5 to 3.8)2.6 (2.0 to 3.3)
SecondaryPercent Change From Baseline in N-Terminal Propeptide Type 1 Procollagen (P1NP)
Time frame:
Baseline, month 1, month 3, and month 6
Reported as:
Median · percent change
Percent Change From Baseline in N-Terminal Propeptide Type 1 Procollagen (P1NP)
percent changePlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mL
Month 12.000 (-5.797 to 16.129)96.296 (67.143 to 159.341)97.435 (69.259 to 126.179)
Month 3-9.601 (-21.503 to 2.922)23.960 (-1.587 to 46.667)16.216 (-10.390 to 50.000)
Month 6-12.500 (-27.500 to 14.286)-2.885 (-28.070 to 18.421)-3.604 (-22.222 to 27.273)
SecondaryPercent Change From Baseline in Serum C-Telopeptide (CTX)
Time frame:
Baseline, month 1, month 3, and month 6
Reported as:
Median · percent change
Percent Change From Baseline in Serum C-Telopeptide (CTX)
percent changePlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mL
Month 10.282 (-16.183 to 12.874)-23.158 (-42.943 to -9.967)-21.456 (-35.602 to -7.246)
Month 3-5.687 (-20.666 to 15.566)-11.219 (-35.206 to 9.484)-5.473 (-24.139 to 26.386)
Month 6-8.120 (-26.935 to 10.059)-25.780 (-43.573 to -8.216)-17.305 (-37.566 to 6.405)

Adverse events

Collected over Adverse events are reported from the first dose of study drug until 90 days after last dose (9 months overall).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo 70 mg—4/26 (15.4%)9/26 (34.6%)
Placebo 90 mg/mL—2/26 (7.7%)5/26 (19.2%)
Romosozumab 70 mg/mL—7/119 (5.9%)24/119 (20.2%)
Romosozumab 90 mg/mL—3/123 (2.4%)38/123 (30.9%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPlacebo 70 mgPlacebo 90 mg/mLRomosozumab 70 mg/mLRomosozumab 90 mg/mL
Mesenteric artery embolismGastrointestinal disorders1/260/260/1190/123
DeathGeneral disorders1/260/260/1190/123
Humerus fractureInjury, poisoning and procedural complications0/261/260/1190/123
Patella fractureInjury, poisoning and procedural complications1/260/260/1190/123
Spinal deformityMusculoskeletal and connective tissue disorders0/261/260/1190/123
Spinal osteoarthritisMusculoskeletal and connective tissue disorders0/261/260/1190/123
Vertebral lesionMusculoskeletal and connective tissue disorders0/261/260/1190/123
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/260/260/1190/123
Medullary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/260/260/1190/123
PolyneuropathyNervous system disorders0/261/260/1190/123
Most frequent other events
Most frequent other events
EventPlacebo 70 mgPlacebo 90 mg/mLRomosozumab 70 mg/mLRomosozumab 90 mg/mL
NasopharyngitisInfections and infestations3/260/269/11919/123
HeadacheNervous system disorders3/260/262/1192/123
AstheniaGeneral disorders0/262/264/1194/123
Upper respiratory tract infectionInfections and infestations1/262/261/1192/123
FallInjury, poisoning and procedural complications2/260/262/1192/123
Bone painMusculoskeletal and connective tissue disorders0/262/262/1192/123
Injection site painGeneral disorders0/260/267/1193/123
Injection site erythemaGeneral disorders0/260/262/1197/123
Urinary tract infectionInfections and infestations0/261/261/1197/123

Baseline characteristics

All randomized participants (full analysis set)

Age, Continuous
Age, Continuous(years)PlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mLTotal
Mean68.4 ± 8.067.4 ± 7.167.7 ± 7.667.7 ± 7.5
Age, Customized
Age, Customized(Participants)PlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mLTotal
< 65 years234646115
≥ 65 years307277179
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mLTotal
Female53118123294
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mLTotal
Hispanic or Latino26917
Not Hispanic or Latino51112114277
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mLTotal
Asian0202
Black (or African American)0101
White53115123291
Lumbar Spine Bone Mineral Density (BMD) T-score
Lumbar Spine Bone Mineral Density (BMD) T-score(T-score)PlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mLTotal
Mean-2.842 ± 1.033-2.965 ± 0.960-3.029 ± 0.687-2.970 ± 0.871
Total Hip BMD T-score
Total Hip BMD T-score(T-score)PlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mLTotal
Mean-2.057 ± 0.634-1.819 ± 0.673-1.828 ± 0.649-1.866 ± 0.660
Femoral Neck BMD T-score
Femoral Neck BMD T-score(T-score)PlaceboRomosozumab 70 mg/mLRomosozumab 90 mg/mLTotal
Mean-2.304 ± 0.517-2.139 ± 0.611-2.018 ± 0.593-2.118 ± 0.595

2 further baseline measures are reported on the registry.

08

Study locations

12 sites
  • Research Site
    Gainesville, Georgia 30501, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Brno, 602 00, Czechia
  • Research Site
    Klatovy, 339 01, Czechia
  • Research Site
    Uherske Hradiste, 686 01, Czechia
  • Research Site
    Gdynia, 81-384, Poland
  • Research Site
    Gliwice, 44-100, Poland
  • Research Site
    Katowice, 40-040, Poland
  • Research Site
    Kraków, 31-501, Poland
  • Research Site
    Swidnik, 21-040, Poland
  • Research Site
    Warszawa, 01-192, Poland
  • Research Site
    Wroclaw, 50-088, Poland
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Sep 2014, 9 months.

Results were first posted in Nov 2018, 4 years 2 months after primary completion. A results delay was requested in Jun 2015.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 9 months is below that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2013
First posted
Dec 20, 2013
StartActual
Dec 3, 2013
Primary completionActual
Sep 8, 2014
CompletionActual
Dec 8, 2014
Results delay requested
Jun 22, 2015
Results first posted
Nov 8, 2018
Last update
Nov 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02016716
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 20, 2013
Start date
Dec 3, 2013
Primary completion
Sep 8, 2014
Completion
Dec 8, 2014
Results posted
Nov 8, 2018
Last update
Nov 8, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion